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Abstract: Drug delivery to the central nervous system (CNS) conferred by brain barriers is a major
obstacle in the development of effective neurotherapeutics. In this review, a classification of current
approaches of clinical or investigational importance for the delivery of therapeutics to the CNS is
presented. This classification includes the use of formulations administered systemically that can
elicit transcytosis-mediated transport by interacting with transporters expressed by transvascular
endothelial cells. Neurotherapeutics can also be delivered to the CNS by means of surgical intervention
using specialized catheters or implantable reservoirs. Strategies for delivering drugs to the CNS
have evolved tremendously during the last two decades, yet, some factors can affect the quality of
data generated in preclinical investigation, which can hamper the extension of the applications of
these strategies into clinically useful tools. Here, we disclose some of these factors and propose some
solutions that may prove valuable at bridging the gap between preclinical findings and clinical trials.
Keywords: CNS-targeted drug delivery; Blood-brain barrier; Receptor-mediated transcytosis;
Transient BBB disruption; Eﬄux-pump inhibition; Ring-opening metathesis polymerization
1. Introduction
Decades of dedicated efforts have led to scientific advances in understanding the physiology of
many diseases and development of a wide array of therapeutic materials. To fulfil their intended
purpose, therapeutic materials must have adequate pharmacokinetics and pharmacodynamics that can
allow them to accumulate in the diseased site in their therapeutically effective concentration. Advances
in the treatment of infections or malignancies residing in peripheral tissues are growing at a faster
pace compared to their CNS-associated equivalents. In large part, this phenomenon is due to the
inability of the therapeutic material to cross brain barriers from the systemic circulation into brain
parenchymal tissues. In this review, we describe the anatomical structure of brain barriers with a
focus on the major contributor to the brain’s strict permeability. We review excerpts of CNS drug
delivery approaches available for clinical use or still undergoing clinical or preclinical trials. We also
highlight the principles underlying their mechanism of action and bring out some of their advantages
and limitations. Finally, we attempt to follow their progress as they weave their way from preclinical
investigation to clinical use.
Targeted drug delivery has found applications in the diagnosis and treatment of many diseases,
such as cancer [1], diabetes [2] and neurodegenerative diseases [3]. As yet, neurodegenerative diseases
remain an area where targeted drug delivery is most needed, since surgical treatments are not always
an option and a treatment at a molecular level is needed. Additionally, intravenously injected
neurotherapeutic materials not only have to evade en route biological barriers, such as solubility in the
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blood stream, stability against enzymatic degradation and phagocytosis, but also barriers interposed
between the systemic circulation and brain tissues [4]. Barriers of the central nervous system (CNS)
are made of specialized cells that lie at the interface between blood and nervous tissues, forming the
blood-brain barrier (BBB), and between blood and cerebrospinal fluid, forming the blood-cerebrospinal
fluid barrier (BCSFB) Figure 1 [5–9]. These specialized cells express transmembrane proteins with
which they can seal off the intercellular space protecting brain tissues from micro-organisms, toxic
compounds and fluctuations in the blood stream that can disrupt synaptic transmission allowing the
brain to efficiently perform its vital functions [5,10]. The BBB is considered as the primary contributor to
the brain’s strict permeability due to its larger surface area and its faster blood flow rate in comparison
to BCSFB [8]. BBB cells are the endothelial cells that line brain vasculature, while BCSFB cells are the
choroid plexus epithelium cells that line the cerebral ventricles and the arachnoid epithelium that line
the brain vasculature in the subarachnoid space [5].
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Figure 1. The t ree main bar ie i the central nervous system (CNS), na ely the meningeal or
arachnoid barrier, the choroid plexus barrier and the blood brain barrier (BBB). The arachnoid and
choroid plexus barriers separate the blood from the cerebrospinal fluid (CSF), and the BBB separates the
blood from the interstitial fluid (ISF). At each site, the barrier is mainly formed by tight junctions that
seal off the paracellular space. The blood brain barrier possesses an intricate architecture of basement
membrane, mural and glial cells that work in synergy to maintain the barrier’s integrity and regulate
its permeability in response to neuronal needs.
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2. Structural Components of the BBB
The major contributor to the BBB occlusion and strict permeability are the tight junctions (TJs) that
seal off the intercellular space between the endothelial cells (ECs) lining the cerebral microvessels [11–13].
TJs (e.g., claudins, occludins and junctional adhesion molecules) are transmembrane proteins that bind
extracellularly to identical transmembrane proteins in adjacent ECs and intracellularly to the actin
component of the filamentous cytoskeleton [11–15]. The occlusion and strict permeability of the BBB is
maintained and regulated by mural and glial cells in response to neuronal activity and needs [11–18].
Mural cells, pericytes and smooth muscle cells, embedded in an extracellular perivascular matrix
termed basement membrane, control the diameter of capillaries, thus regulating blood flow and immune
cell infiltration [10,13,19]. Astrocytes, a component of glial cells, ensheath the ECs, mural cells and the
extracellular matrix, supporting blood vessels’ architecture and maintaining BBB integrity [5,10,11,20].
Astrocytes secrete chemical reagents that modulate BBB permeability in response to neuronal signals,
providing the cellular linkage between neuronal circuitry and blood vessels [5,10,11,20]. Together, the
TJs, pericytes and astrocytes form the physical components of the BBB.
Due to the absence of vascular fenestrae, molecules (e.g., nutrients, electrolytes, metabolic waste
and potentially therapeutic material) are translocated across the BBB’s vascular endothelium via
specialized transporters (Figure 2) [5,10,16,21–23]. Nutrients, such as glucose, amino acids, peptides
and proteins, are actively transported down their concentration gradient from the vascular lumen
to the brain parenchyma via carriers or receptors expressed at the luminal and abluminal plasma
membranes of the BBB’s ECs [5,10,22]. Influx of electrolytes, e.g., Na+ and K+, is regulated by ion
pumps residing on the abluminal surface of EC membranes [16,24]. Potentially toxic substances,
such as amyloid-beta, a peptide implicated in the pathology of Alzheimer’s disease, are cleared from
the brain parenchyma by receptors expressed at the abluminal membrane [10,16]. Small molecules,
e.g., CO2, O2 and lipophilic molecules, with molecular weights <400 Da, are able to passively diffuse
through the lipid bilayer membranes of ECs [5,10,16,22,23].
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and organic anion olypeptide (OATPs). Protein and peptide transporters d picted in red are
the transferrin receptor (TfR), insulin receptor (IR) and low-density lipoprotein receptor-related
protein (LPR). Multidrug-resistance-associated proteins and P-glycoprotein, depicted in yellow and
purple, respectively, are eﬄux pumps that transport xenobiotics against their concentration gradient.
Electrolytes are regulated by ion exchangers such as Na+/K+-ATPase pump.
The passive diffusion of small lipophilic molecules through the lipid bilayer across the BBB, in most
scenarios, is counteracted by enzymatic metabolism or active eﬄux from vascular endothelium into
the blood [5,10,25]. Active eﬄux is accomplished by ATP-binding cassette transporters (ABC), such as
P-glycoprotein (P-gp), breast cancer resistance proteins (BCRPs) and multidrug resistance-associated
proteins (MRPs) [10,16,22,23]. ABC transporters are transmembrane proteins that use the hydrolysis
of adenosine triphosphate (ATP) as the driving force for the translocation of their substrate against
the substrates’ concentration gradient [26]. Albeit essential to protecting brain homeostasis and
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vitality against foreign molecules, eﬄux transporters pose additional hurdles in the delivery of
neurotherapeutics across the BBB due to their broad substrate scope [27,28].
2.1. Strategies for Delivery of Therapeutics Across the BBB
Technical strategies for the delivery of therapeutics across the BBB, as we shall see, are broadly
divided into two main categories—delivery beyond and through the BBB. Delivery beyond the BBB
bypasses the BBB altogether by injecting the therapeutic material directly into the brain tissues.
Delivery through the BBB can be achieved either by enhancing the physicochemical properties of
the therapeutic material, inhibition of eﬄux pumps, transient disruption of the BBB or by exploiting
endogenous transport mechanisms employed by ECs for the translocation of nutrients. In this section
we will present examples of both approaches and highlight the underlying principles and some of the
advantages and disadvantages.
2.1.1. Drug Delivery Beyond the BBB
Intraparenchymal Drug Delivery
Intraparenchymal drug delivery is the direct injection of therapeutic material in the brain
interstitium (Figure 3) [29–31]. Brain interstitium is the region lying within the extracellular and
extravascular space in brain parenchyma [29,31]. The space is occupied with interstitial fluid, which
consists of water, salts, sugars, fatty acids, amino acids, hormones, neurotransmitters and other
nutrients [29–31]. Injecting the therapeutic material directly in the brain interstitium allows it to reach
different regions in the brain by traversing the interstitial space [29–31]. Due to its interspersion with
cells and capillaries, the interstitium is an inhomogeneous and anisotropic environment and can often
be altered by a disease’s pathological state [29–31]. In practical terms, this means that injection is
associated with inevitable, and sometimes permanent, damage to nearby tissues [29]. Additionally, the
procedure is fraught with technical complications, such as inadequate infusate diffusion, and in some
cases, backflow [29].
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Figure 3. Direct delivery of therapeutic material into the brain interstitial space using a specialized
cathet r. The in erst tial space is occ pied with inters itial fluid (ISF). Directly injected therapeutic
m terial diffuses through the ISF and acc sses different regions of brain parenchyma.
Intraventricular and Intrathecal Drug Delivery
The therapeutic material is directly administered in one of the ventricles (intraventricular) or
the spinal canal (intrathecal) as time-separated boluses via an internally implanted reservoir or a
programmed pump (Figure 4) [32–35]. The therapeutic material reaches the brain and spinal cord
tissues through the CSF [32–35]. Replenishment of the therapeutic material can be achieved by topping
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up the reservoir or replacing the pump [32–35]. The installation of the catheter and the reservoir or
the pump is performed surgically, thus, as with all surgical manipulations, there is a risk of tissue
damage, accompanied with a loss of function, and tissue infection with the added recovery time of the
patient [32–35]. The extent of such risks can be reduced by careful planning of the operation, use of
orthogonal technologies that can help visualize the route of implantation, and antibiotic prescription,
if necessary [32]. In some cases, intraventricular or intrathecal drug administration is the most
cost-effective approach for the treatment of chronic pain secondary to brain or spinal cord injury by
sustaining a prolonged and stable state of analgesia without developing addiction or severe side effects,
thereby improving patients’ quality of life [32].
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Figure 4. Direct delivery of the therapeutic material to the central nervous system (CSF) in the
subarachnoid space of the spinal canal (intrathecal delivery) or brain ventricles (ventricular delivery)
as time-separated boluses via an implantable reservoir. The injected therapeutic material traverses
the CSF, accessing different regions of the CNS. The reservoirs are toped up by pump replacement or
direct injection.
Intranasal Drug Delivery
Therapeutic material administered intranasally can reach the CNS via three transport routes;
the olfactory pathway, the trigeminal pathway and the systemic circulation pathway [36,37].
The olfactory and trigeminal pathways bypass the BBB by delivering the therapeutic material from
the nasal cavity to the brain tissue via passive or active transport mechanisms along the olfactory
nerves or trigeminal nerve branches that innervate the nasal cavity (Figure 5) [36,37]. As for the
systemic circulation pathway, the therapeutic material must diffuse through the mucus, cross the nasal
epithelium by passive or active transport, enter the venous blood flow to reach the CNS, then overcome
the BBB [36,37]. The olfactory and trigeminal pathways are the direct nose-to-brain transport routes
in this scenario and are much less invasive than the intraparenchymal and intraventricular routes.
However, these pathways are limited by the small amount of therapeutic material that can successfully
reach the brain tissue, relative to the amount administered [36,37].
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2.1.2. Drug Delivery Through the BBB
Optimizing the Physicochemical Properties of Therapeutic Materials
To fulfil its intended purpose, a drug must exh bit high potency and selectivity towards the
biological target, as well as reach a concentration above an experimentally determined threshold within
brain tissue [25]. Drug concentration in the brain, Cbr, is influenced by the concentration of the drug in
its free form in the blood stream, as described by Equation (1), where Kin is the unidirectional influx
constant [38,39].
Cbr = Kin ×AUC0T (1)
The concentration of the therapeutic material in its free form in the blood pool, expressed as the area
under the plasma concentration-time curve (AUC0T), is affected by its pharmacokinetic properties [25].
Pharmacokinetic refers to how the host’s body acts on the therapeutic material once it’s administered
by absorption, distribution, metabolism and excretion processes (Figure 6) [25,38,39]. Therefore,
opti izing the physiochemical properties of drug candidates to evade these processes has become
an integral part of the drug discovery paradigm [25,40,41]. In this context, the most detrimental
physiochemical properties are lipophilicity, hydrogen bonding, molecular flexibility and molecular
volume [25,40,41]. Drawn from literature precedents in this area, lipophilicity, hydrogen bonding
and molecular flexibility follow a parabolic curve that exists between these properties and the drug’s
distribution in the brain [25]. Increasing the lipophilicity improves the solubility of drug candidates in
ECs’ lipid membranes but it can negatively affect the drug’s absorption, and consequently its AUC0T,
due to insufficient solubility in the blood stream [25,42,43]. Increasing the number of heteroatoms
capable at forming hydrogen bonds may resolve drug absorption limitations as a result of increased
hydrophilicity [25]. Nonetheless, it can introduce other issues, such an increase in free energy of
desolvation due to the enthalpy penalty associated with the polar groups desolvation, which is a
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process the drug must undergo as it approaches the ECs’ lipid membranes and attempts to initiate a
dipole interaction with its components [25,44]. Additionally, increased polarity and/or lipophilicity
may enhance drug binding to serum proteins via H-bonding and lipophilic interactions, respectively,
which, in turn, reduces its AUC0T, and therefore, Cbr [25,45]. Molecular flexibility, induced by rotatable
bonds, allows the drug molecule to wiggle through the long chains of the membrane lipids [25,46].
However, excessive molecular flexibility may have the opposite effect if the drug molecule can adopt an
array of conformations among which are bulky geometries [25,46]. As for molecular volume which is
a function of molecular weight and structure including all accessible conformations the drug molecule
can adopt under the physiological conditions, the more compact it is the greater is the likelihood of the
drug traversing the BBB by passive diffusion through its ECs’ LBL membranes [25]. Retrospective
analysis of CNS and non-CNS active drugs that had entered at least phase II of clinical trials determined
the general physicochemical properties required for BBB penetration and has guided the synthesis of
novel analogues [25]. The growth of computing power allowed the development of computational
algorithms that can predict the physicochemical and pharmacokinetic properties of drug candidates
and their capacity to bypass the BBB [25].
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Figure 6. Biological barriers that the therapeutic material encounters upon intravenous injection
that can reduce the blood-circulation lifetime of the therapeutic material. This can co pro ise the
phar acokinetic of the therapeutic material and ultimately its effectiveness. Biological barriers include
water-solubility in the blood stream, drug absorption, inadequate biodistribution, biotransformation by
enzymatic degradation, and clearance by immune system and excretion by glomerular filtration.
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Inhibition of Eﬄux Proteins
Inhibition of eﬄux pumps allows systemically administered drugs that can passively cross the BBB
to accumulate in the brain and reach their therapeutically effective concentration [47–51]. The inhibitor,
typically co-administered with the drug, can attenuate the activity of eﬄux pumps by competitively
or allosterically blocking the drug binding site or by interfering with ATP hydrolysis that drives
the eﬄux of substrates against their concentration gradient (Figure 7) [48,51]. In pre-clinical studies,
co-administration of elacridar, a P-gp allosteric modulator, with paclitaxel, a chemotherapeutic agent,
was shown to increase the latter’s brain uptake in mouse models relative to matched controls [50,51].
Eﬄux transporters are ubiquitously expressed in several human tissues, such as kidneys and liver,
therefore the pharmacokinetic fate of therapeutic material co-administered with eﬄux inhibitor is
often unpredictable [52,53]. Whereas down-regulation of eﬄux transporters’ activity can enhance
brain uptake of the therapeutic material, it can also increase brain uptake of potentially toxic materials.
Therefore, the risks associated with long-term therapy utilizing this approach must be carefully weighed.
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Eﬄux inhibitors may compete for eﬄux pump-mediated extrusion, which favors intraparenchymal
accumulation of substrates (A), and may bind to a site distinct from the primary substrate binding
site causing the protein to undergo a conformational change that blocks the substrate binding site (B)
or may interact with the ATPase binding site in the eﬄux pump, obstructing production of energy
required to transport substances against their concentration gradient.
Transient Disruption of the Blood–Brain Barrier
Hyperosmotic Disruption of the BBB
Intracarotid injection of a yperosmotic solution such as arabinose or mannitol prior to intraarterial
administration of chemotherapeutic agents was shown to substantially raise the latter’s concentration in
the brain parenchyma [54,55]. The hyperosmotic solution causes water to be withdrawn out of the ECs
into the vascular lumen, resulting in shrinkage of the ECs (Figure 8) [54,55]. Shrinkage of the ECs causes
their cytoskeleton to horizontally contract, whose effect propagates through the cytoskeleton’s actin
component, TJs’ adapter proteins, and finally reaches the TJs proteins [54,55]. The downstream effect
is an increased bulk fluid flow across the tight junctions into brain parenchyma [54,55]. The transient
disruption induced by this hyperosmotic method lasts for a short period of time—15 min to 4 h—the
length of which can be modulated by varying hyperosmotic solution concentration and infusion
time [54,55]. The hyperosmotic disruption technique is non-specific with respect to the cerebral and
brain tissue it can affect. The hyperosmotic solution can circulate in the blood stream and induce its
affect in several brain and, potentially, body regions [55]. Despite its low morbidity rates, hyperosmotic
disruption of the BBB is associated with transient cerebral edema due to increased bulk fluid influx.
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This can severely aggravate neurological defects, especially if such treatment regimen is to be prescribed
repeatedly [54].
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Figure 8. Transient BBB disruption by treatment with a hyperosmotic agent. The hyperosmotic solution,
typically co-injected with the therapeutic material, causes water to be withdrawn out of the ECs,
resulting in their shrinkage, contraction of their cytoskeleton and disruption of their TJs, allowing the
paracellular diffusion of the co-administered therapeutic material.
Microbubble-Assisted Focused Ultrasound Irradiation (MB-FUS)
Image-guided focused ultrasound (FUS) emerged as an alternative approach for the induction
of transient BBB disruption after it had for been tested for a long time as a non-invasive thermal
ablation technique for the treatment of brain tumors [56–58]. Early investigations of FUS-induced BBB
disruption and its bioeffects on brain tissue reported the occurrence of tissue damage that manifested
itself as lesions or necrosis due to exposure to high frequencies of FUS [59–63]. Intravenous injection of
preformed microbubbles prior to FUS exposure prevented tissue damage by attenuating the effective
FUS power levels [64–67]. The microbubbles, which are typically commercially accessible lipid or
albumin shells encapsulating gaseous material, such as Optison, harness the acoustic power and
concentrate it to the blood vessel walls maximizing its efficiency, and thus, lowering the threshold of
effective power levels (Figure 9) [64–67]. Circulating micro-bubbles move in the direction of the FUS
wave propagation and are brought in close contact with the vessel’s ECs [64–67]. Depending on their
size and the acoustic power level, microbubbles can oscillate, micro-streaming the medium surrounding
them, expand, or collapse, exerting mechanical stress on ECs, modifying their membranes and the
tight junctions between them [64–67]. The transient disruption induced by microbubble-assisted
FUS lasts for a short period of time, from 4 to 6 h, the length of which can be modulated by tuning
pulse duration, pulse frequency, exposure time and microbubbles’ diameter [64–67]. The success of
trans-BBB delivery following a microbubble-assisted FUS BBB-disruption event was demonstrated
for a broad spectrum of therapeutic materials, including liposome-encapsulated and antibody-based
anticancer agents [64,68,69]. Orthogonal techniques, such as magnetic resonance imaging (MRI), have
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been used to visualize and monitor the process in real-time to ensure adequate optimization of the BBB
disruption parameters and deep tissue targeting with efficient spatial resolution [64–67]. Minimizing
aberrations in the phase and amplitude of FUS waves caused by the skull acoustic impedance remains
the major challenge of this approach [64,70]. Correction for FUS beam aberrations introduced by the
skull, whose thickness varies amongst species, requires determination of the acoustic properties of
the test subjects’ skull. This can be achieved by CT scanning, and integrating the resulting data in
aberration correction algorithms [64,70]. Correction of abrasions, together with the multiple MRI
acquisitions and analysis, makes this approach time consuming, and considering the amounts of both
ultrasound and MRI contrast agents, may not always be cost-effective.
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Figure 9. Principle of BBB disruption using MRI-guided microbubble-assisted focused-ultrasound
technique (MB-FUS). (A) The patient’s head is rested in a semi-spherical ultrasound transducer
integrated into an MRI scanner. The transducer is attached to a mechanical positioning system.
The focused ultrasound and the magnetic resonance parameters are remotely controlled by electronic
interfaces. The patient’s head is immobilized by a stereotactic frame. Overheating of the scalp, skull
and brain tissue is minimized by the use of a water interface, which also acts as an acoustic coupler.
(B) Pretreatment of the patient with microbubbles harnesses the acoustic power and concentrates it to
the blood vessel, which attenuates acoustic power levels. Microbubbles move in the direction of the
FUS wave propagation and under the influence of the FUS waves they oscillate, micro-streaming the
mediu surrounding them, inducing mechanical stress that disrupts the TJs between ECs. Figure 9 (A)
adapted from Martin et al. [57].
The mechanism by which TJs protein impairment is evoked, including how hyperosmotic
or echanical stress contribute to this i pairment, remains unknown. In independent studies,
im unoelectron microscopic examinatio after y eros otic and FUS-induce disruption showed
both redistribution and loss f i signals of TJ proteins in aff cted brain regions [67,71]. Loss
of nosignals can be a tributed to disintegration, denaturation or conformational change in TJs’
protein structure [67, 1]. The major conc t B disruption techn logie is that during
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the therapeutic window, the CNS remains unprotected against blood-borne toxins, such as bacteria
and viruses, and blood components that are considered neurotoxic. Therefore, the technique requires
careful planning, monitoring and optimization of the therapeutic window to ensure optimal therapeutic
efficacy and reduced side effects.
2.1.3. Drug Delivery Using Novel Formulations
Designing drug candidates with balanced physicochemical properties that can simultaneously
sustain an adequate pharmacokinetic profile of the drug and conquer the BBB remains a very challenging
aspect. Such challenge can be offset, as discussed below, by designing sophisticated formulations that
can exploit the innate transcytosis capacity of transporters expressed by ECs of the BBB. This can be
achieved by ligation of the therapeutic material to a vector whose binding to an EC transporter can
elicit a transcytosis event. EC transporters targeted to fulfill this purpose fall into three major categories:
solute carriers, protein and hormone receptors, and negatively charged membrane entities. Although
some of these transporters are bidirectional, the flux direction is generally set by the concentration
gradient from high intravascular to low intracerebral [72]. Exemplary EC transporters that participate
in such delivery modality are briefly reviewed in this section, along with prototypical examples of
formulations designed to target them.
Solute Carrier-Mediated Transcytosis (CMT)
The detailed mechanism of elicited solute carrier-mediated transcytosis (CMT) is believed to
proceed via carrier–vector recognition at the luminal side followed by a conformational change of
the carrier from outward to inward-facing states, resulting in the transport of the substrate down its
concentration gradient across luminal and abluminal membranes of the ECs (Figure 10) [73]. Solute
carrier transporters (SLC) are bidirectional and are expressed at both the luminal and abluminal
membranes to ensure the translocation of their substrates into the ECs through the luminal membrane
and out through the abluminal membrane, without sequestration within the capillary endothelium [11].
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Figure 10. Postulated mechanism of carrier-mediated transcytosis (CMT). Solute carrier transporter
proteins (SLC) undergo conformational change from outward to inward-facing orientation, translocating
their substrates across luminal and abluminal membranes from high intravascular to low intracerebral.
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Glucose Transporters (GLUTs)
Transport of glucose across the BBB is facilitated by several glucose transporters, of which the
most prevalent is the sodium-independent bi-directional transporters family (GLUTs) [74]. Due to
their abundance, glucose transporters gained significant attention as a potential drug delivery route
across the BBB [75,76]. In pre-clinical studies, glycosyl conjugates, d-glucos-6-yl ester, in particular,
of the BBB-impermeable antidepressant 7-chlorokynurenic acid were shown to be more potent as
neuroprotective agents against seizures induced by N-methyl-d-aspartate (NMDA) in mouse models
(Figure 11) [77,78].
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Figure 11. Structure of sugar-conjugates designed to highlight the structural requirements of
GLUT-mediated transport of therapeutic material. Compounds 1–3 are glucose and galactose conjugates
of the BBB-impermeable antidepressant 7-chlorokynurenic acid. Compounds 4–7 are glucose and
galactose conjugates of l-DOPA, a dopamine precursor used for the management of Parkinson’s
disease symptoms. Compounds 8 and 9 are glucose conjugates f c lorambucil, a BBB-impermeable
chemotherapeutic reagent. The three studies revealed the sensitivity of this approach to the conjugate’s
size and the lig tion regiochemistry of its cargo.
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Similarly, glycosylation of l-DOPA, an FDA approved dopamine metabolic precursor used
for the management of Parkinson’s disease symptoms, was shown to significantly reverse the
reserpine-induced hypolocomotion (Figure 11) [79,80]. In contrast, attempts to deliver glycosylated
chemotherapeutic reagents across the BBB failed by comparison. Not only were glycosyl conjugates of
structurally larger molecules—such as chlorambucil, a chemotherapy medication used to treat chronic
lymphocytic leukemia—not transported by GLUTs, but they also inhibited the uptake of 14C-labelled
glucose (Figure 11) [81]. Albeit reversible, the inhibitory activity of glycosyl conjugates of chlorambucil
deemed this approach limited by its high selectivity toward a specific molecular size [81].
Large Neutral Amino Acid Transporters (LATs)
The large neutral amino acid transporters (LATs) are transporters associated with the translocation
of neutral amino acids that contain relatively large and lipophilic substituents on the α-carbon, such as
l-tyrosine and triiodothyronine, across biological membranes [82–84]. Pharmacologically significant
LATs substrates include the prodrug l-DOPA, used as dopamine replacement in Parkinson’s disease
therapy, melphalan, used as a chemotherapeutic agent, and gabapentin, prescribed as anticonvulsant
medication (Figure 12) [83,84]. By analogy with GLUTs, LATs are highly selective toward the substrate’s
size, conformational rigidity and regiochemistry of its substituents, which can limit this drug delivery
approach to a small group of therapeutic materials [83]. Additionally, LATs were found to competitively
bind to some of its substrates, which can inhibit their ability to transport other essential amino acid
nutrients [83,84].
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which bind to opioid receptors expressed throughout brain, spinal cord and peripheral nerves, 
inducing an analgesic effect against pain secondary to inflammatory pathological conditions (Figure 
13) [86,87]. 
 
Figure 12. Structure of large amino acid substrates of large neutral amino acid transporters (LATs).
l-DOPA, a dopamine precursor, gabapentin, an anticonvulsant, and melphalan, a chemotherapeutic
reagent, are the pharmacologically relevant LAT substrates. Compounds 13–15, derivatives of
melphalan, were designed to highlight the structural requirements of LAT-mediated transport of
therapeutic material. The study revealed the sensitivity of this approach to the conformational rigidity
and regiochemistry of substituents of LATs substrates.
Organic Anion Transporting Polypeptide (OATPs)
Organic anion transporting polypeptide (OTAPs) are protein transporters that mediate the
transport of a wide variety of endogenous amphipathic organic substrates, including steroid conjugates,
thyroid hormones, bile salts, and oligopeptides [85]. A growing body of pre-clinical studies
demonstrated OTAPs’ capacity to transport oligopeptides, such as DPDPE and deltorphin, which
bind to opioid receptors expressed throughout brain, spinal cord and peripheral nerves, inducing an
analgesic effect against pain secondary to inflammatory pathological conditions (Figure 13) [86,87].
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Figure 13. Structure of oligopeptides transported by organic anion transporting polypeptide carriers
(OTAPs). Identification of DPDPE and deltorphin as OTAPs substrates can inspire the design of
neurotherapeutic material or OTAPs-targeting ligands that mimic their structure.
Receptor-Mediated Transcytosis (RMT)
In receptor-mediated transcytosis (RMT), a receptor–vector recognition event occurs at the luminal
side (Figure 14) [88]. This first point of entry is followed by endosome formation, which pinches
the luminal membrane and transports the cargo across the endothelial cell to the opposite end [88].
Transcytosis ends with exocytosis of the cargo at the abluminal side and recycling of the receptor back
to the luminal surface of the membrane, free to engage in another RMT cycle [88]. The limiting step in
achieving an effective delivery of neurotherapeutics across ECs is the prevention of lysosomal sorting,
leading to degradation of the neurotherapeutic cargo.
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Insulin Receptor (IR)
The insulin receptor (IR) facilitates the transport of insulin, produced nearly exclusively by the
pancreas, across the BBB so it can contribute in an array of vital signaling pathways [89]. Engineered
monoclonal antibodies with a binding affinity towards the IR can be used to ferry therapeutic materials
across the BBB via IR-mediated transcytosis. Erythropoietin (EPO), a neurotrophic factor that supports
the growth, survival, and differentiation of neurons, is a protein whose development as a potential
therapeutic material for treatment of neurological disorders is restricted by its inability to traverse the
BBB [90,91]. Re-engineering of EPO by its genetic fusion to a peptidomimetic monoclonal antibody with
an affinity to human insulin receptor (HIRMAb) was shown to markedly increase its brain uptake after
intravenous injection into adult rhesus monkeys relative to the native EPO control (Figure 15) [91,92].
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Transferrin Receptor (TfR)
The transferrin receptor (TfR) is a transmembrane glycoprotein, whose function is to mediate
the cellular uptake of Fe-bound Tf [93]. Tf is a member of Fe-binding glycoproteins family and a
protein of vital importance for the proliferation, growth, and differentiation of cells [93]. In preclinical
studies, anti-TfR monoclonal antibody drug conjugates, such as anti-TfR antibody-methotrexate,
a chemotherapeutic agent, were shown to exhibit an enhanced uptake into the brain parenchyma
relative to their antibody-free analogues (Figure 16) [94]. The versatility of this approach encompasses
not only the delivery of small molecules but also offers a potential delivery route for peptides and
neurotrophic factors. Owing to its enhanced transport across the BBB, an anti-TfR monoclonal
antibody-EPO conjugate intravenously injected into mouse stroke models dramatically reduced the
hemispheric stroke volume compared to its antibody-free counterpart [95].
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Figure 16. Structure of anti-rat transferrin receptor monoclonal antibody (TfRMAb) engineered to
deliver methotrexate ( TX) to the brain by exploiting transferrin receptor-mediated transcytosis.
The TfRMAb-MTX conjugate in this example was prepared by oxidation of the carbohydrate groups
located on the Fc portion of the TfRMAb to form an aldehyde derivative, which was treated with a
hydrazide-functionalized MTX forming a hydrazone-linker between MTX and TfRMAb.
Low-Density Lipoprotein Receptor (LDLR) and Low-Density Lipoprotein Receptor-Related
Protein (LPR)
The low-density lipoprotein receptors (LDLRs) and LDLR-related proteins (LRPs) are
multifunctional members of the LDLR superfamily, which is engaged in a wide range of physiological
processes, including the regulation of cholesterol homeostasis by receptor-mediated uptake of
cholesterol-transporting low-density lipoproteins [96]. Ligands that can stimulate LDLs and
LRPs-mediated transcytosis across the BBB, such as angiopep, were derived from LDLRs and LRPs
substrates, such as amyloid precursor protein (APP) and aprotinin, in particular their Kunitz protease
inhibitor domain [97,98]. An angiopep-paclitaxel conjugate (ANG1005) was shown to be significantly
more effective at bypassing the BBB and accumulating in brain parenchyma, compared to the
free paclitaxel, after its intravenous injection into brain-metastasized breast cancer mouse models
(Figure 17) [99].
. . . . , ,        
 
Figure 17. Structure of the paclitaxel-Angiopep-2 conjugate (ANG1005) engineered to deliver paclitaxel
to the brain by exploiting low-density lipoprotein receptor-related protein (LRP)-mediated transcytosis.
Angiopep-2 was discovered by sequence alignment of LRP substrate proteins, such as amyloid
precursor protein (APP) and aprotinin. Paclitaxel is released upon hydrolysis of ester linkages by
hydrolyzing enzymes.
Int. J. Mol. Sci. 2019, 20, 3108 17 of 43
Neurotropic Virulence Factor Receptors (VFRs)
Virulence factors are molecules produced by a pathogen to allow it to enter, replicate, and persist
in a host organism’s body [100]. A prominent example is the neurotropic rabies virus (RV), which
recruits its external glycoprotein (RVG) to bind to the nicotinic acetylcholine receptor, membrane
fusion and host-cell entry [101–105]. The well-characterized mechanism of RV cellular entry inspired
the development of a CNS-drug delivery motif, which utilizes RVG-derived peptides as the delivery
vector [101–105]. In preclinical gene silencing studies, GFP transgenic mouse models were intravenously
injected with GFP-specific small interfering RNA (siRNA) non-covalently conjugated to a chimeric RVG
fragment peptide (Figure 18) [103]. Conjugation to RVG fragment peptide enabled the translocation
of GFP specific siRNA across the BBB and GFP gene expression was significantly suppressed in the
brains of test subjects relative to their other major organs [103].
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Figure 18. Schematic representation of the structure of rabies virus glycoprotein-derived peptide (RVG)
in complex with GFP-siRNA. The conjugate was engineered to deliver GFP-siRNA to the brain by
exploiting nicotinic acetylcholine receptor-mediated transcytosis. To enable the complexation of RVG
to GFP-siRNA, RVG was coupled to a nona-d-arginine peptide (9dR) through a tri-l-glycine spacer.
Adsorptive-Mediated Transcytosis (AMT)
Similarly to RMT, adsorptive-mediated transcytosis (AMT) proceeds with an invagination of the
AMT-substrate followed by endosomal formation and transport from the luminal to the abluminal
side, ending with exocytosis of the endocytosed cargo [47,106–108]. Unlike RMT, AMT is triggered by
an electrostatic interaction between the AMT-vector and anionic proteoglycans, such as syndecan-4
(Figure 19A) [109,110]. AMT-vectors can be derived from naturally occurring proteins or peptides
and are typically short, not exceeding 30 amino acid residues, and feature hydrophobic residues and
residues that are positively charged under physiological conditions [111–116]. Vectorization by ligation
to cell-penetrating peptides, such as SynB1, a peptide derived from an antimicrobial peptide isolated
from porcine leucocytes, was shown to markedly enhance brain uptake of poor BBB-penetrating drugs,
such as cysteamide-modified dalargin, doxorubicin, and benzylpenicillin (Figure 19B) [113,117–119].
The most attractive attribute of drug delivery facilitated by AMT is that it does not interfere with
endogenous cellular functions the way CMT or RMT-mediated drug delivery do. To date, there are
no records, to our knowledge, that can demonstrate an interference of AMT with cellular signaling
pathways. Additionally, binding sites are saturated at higher concentrations in AMT than they are in
CMT and RMT [38,91,120,121].
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Figure 19. Delivery of therapeutics to the brain by exploiting adsorptive-mediated transcytosis (AMT)
of the delivery vectors with anionic proteoglycans, such as syndecan-4. (A) Structure of syndecan-4.
Syndecan-4 is a proteoglycan that is a heavily glycosylated transmembrane protein. The protein
consists of an extracellular domain that carry one or more covalently attached glycosaminoglycan
(GAG) chain(s). GAG chains are long, linear carbohydrate polymers that are negatively charged
under physiological conditions due to the presence of sulfate and uronic acid groups. The GAG chain
allows for the interaction with a large variety of li a s, s c as ro th factors and enzymes. GAG
chains are attached to the extracellular i t a tetra-sa charide bridge (GlcA-Gal-Gal-Xyl).
(B) Struct re of SynB1 drug conjugates of cy teamide-modified dalargin, n analgesic drug, doxorubicin,
a chemotherapeutic agent, and benzylpe icillin, an antibiotic that exploits AMT to trigger brain up ake
of its th rapeutic c rgo.
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Nanoscopic Formulations for the Delivery of Therapeutics to the Brain
Nano-formulations have emerged as platforms that allow the modification of the pharmacokinetic
or pharmacodynamic properties of therapeutic materials without dramatically modifying their
chemical structure (Figure 20). Because clearance of therapeutic material by excretion is dependent on
its molecular weight, nano-formulations are designed to increase the apparent therapeutic material’s
hydrodynamic volume, reducing its rate of excretion [4,122]. Nano-formulations are also designed
to mask the therapeutic material’s functional groups detectable by the host’s immune system, serum
proteins and enzymes, prolonging its circulation half-life [122–125].
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Figure 20. The pharmacokinetics and phar acodynamics aspects that determine the fate of the
therapeutic material and ability to accumulate i t e diseased site at its therapeutically effective
concentration. Pharmacokin erapeutic material can be improved by altering the
physicochemical properties to re the rate of drug disp sition by excretion or etabolism.
The phar aco ynamics can be improved by optimizing the echanism of action or the cellular
targeting capacity. Altering pharmacokinetics or pharmacodynamics without negatively effecting the
other is a challenging aspect of drug and drug-formulation design. An optimal drug or drug-formulation
is a design with balanced pharmacokinetics and dynamics.
Some nano-formulations are engineered with an intrinsic capacity to deliver therapeutics across
brain barriers, such as SGT-53, while others are engineered to deliver therapeutics with the aid of
recently developed techniques that transiently disrupt the BBB, such as Doxil® (Figure 21) [69,126].
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Nano-formulations of several therapeutics have been approved by the Food and Drug Administration
(FDA) and are commercially available, such as Doxil® and Onivyde®, and some are currently under
preclinical and clinical trials, such as NU-0129 and OnzealdTM [127,128].
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Figure 21. Nanoscopic formulations for the delivery of therapeutics to the brain. NU-0129 is a gold
nanoparticle formulation whose surface is conjugated ith of polyethylene glycol chains and small
interfering RNAs (siRNAs) that target the Bcl-2-li e r tei . -0129 is currently under clinical trial
for its anti eoplastic activity and potenti l i t t t ent of recu rent glioblastoma multiforme.
SGT-53 is a cationic liposome in complex with its tic therapeutic material. The lip somal
surface is conjugated with a sfe rin receptor single-chain antibody fragment that serves
as t r eting vector. SGT-53 is currently under clinical trial for its poten ial to induce apoptosis
in ts it rrent li blastoma. Onzeald ® (or et rinotecan pegol) is a pegylated rinotecan
formulation with a long-acting effect. Onzeald TM is currently under clinical tri l to evaluate its efficacy
at the control of brain metastases. Onivyde® and Doxil® are liposomal formulations that encapsulate
irinotecan and doxorubicin, respectively, in an aqueous space. The liposomal surface of Onivyde®
and Doxil® is conjugated with chains of polyethylene glycol to improve their colloidal stability and
non-immunogenicity. Because of their long-acting effect, Onivyde® and Doxil® are under clinical
trials to evaluate their efficacy at treating patients with glioblastoma. Doxil® is also under pre-clinical
investigation to assess its efficiency at the treatment glioblastoma after transient disruption of the BBB
induced by microbubble-assisted focused ultrasound (MB-FUS).
Developing drug delivery strategies that can overcome the BBB and selectively target the
mitochondria is of great interest, since mitochondrial dysfunction has been implicated in the
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pathology of several neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease,
and cancer [129–132]. Mitochondrial targeting ligands exploit the mitochondrial inner negative
potential to stimulate mitochondrial uptake [133–135]. Mitochondrial-targeting ligands share
similar structural features with AMT ligands. They are small, hydrophobic and positively charged
molecules [133–135]. One of the important questions we look forward to answering is if the positive
charge of mitochondrial-targeting ligands delocalized over their hydrophobic phenyl rings can elicit
an AMT-like transport of mitochondrial-targeting conjugates or whether mitochondrial-targeting
conjugates require the use of orthogonal techniques that can transiently disrupt the BBB, such as
MB-FUS. We set out to test these hypotheses by designing nanoscopic polymeric brush-like architectures
(NPBAs) conjugated with mitochondrial-targeting ligands (Scheme 1). Our group prepared a
fluorescent mitochondrial-targeting NPBA prototype via Ring Opening Metathesis Polymerization
technique (ROMP).
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iodide as the mitochondrial targeting ligand. The block-co-polymers, poly(NorbEO12Coumarin-co-
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ROMP initiated by Grubbs third generation ruthenium-benzylidene catalyst has been regarded as
a powerful tool for the synthesis of graft-through nanoscopic brush architectures with a predictable
number average molecular weight, Mn, and a narrow molecular weight distribution, Ð (Scheme 1;
Box 1) [136,137]. Triphenylphosphonium ligands have emerged as economically and synthetically
accessible mitochondrial-targeting systems that can be accessed from alkyl-halides via a substitution
reaction using PPh3 as the nucleophile in a pre-polymerization step [138,139].
A range of commercially available hydrophilic polymers, such as chitosan, polyethylene glycol
and poly(N-(2-hydroxypropyl)methacrylamide), can be used for the hydrophilic skeleton design, but
because polyethylene glycol has only two terminal functional groups, its functionalization is practically
more precise to accomplish and monitor [122]. Additionally, the ethylene glycol oligomers can be
prepared in-house in good yields and with high oligomeric purity via oligomerization of tetraethylene
glycol [122,140]. The diethylamino coumarin derivative proved useful as a fluorescent tag due to its
two-photon fluorescence, which can be induced via illumination with a stream of a pulsed near-infrared
laser beam with a pulse duration and repetition rate of 100 fs and 80 MHz, respectively [122,141–143].
The optical consequence of two-photon fluorescence is the confinement of the fluorescent region to a
smaller volume than that of conventional one-photon fluorescence [122,141–143]. In practical terms,
this leads to suppression of out-of-focus fluorescence, which enhances the resolution of the image and
minimizes photobleaching of fluorophore molecules and photochemically-induced cytotoxicity of the
live specimen [122,141–145]. Nonetheless, the optical probe is a bright UV-Vis, excitable fluorescent
dye that can generate good images with a conventional confocal microscope [122,141]. Preliminary
mitochondrial-uptake assessment of NPBA-I conducted employing a monolayer of SH-SY5Y cells
showed promise but more effort is still needed to bring this idea to its full potential.
Box 1. Advantages of ROMP in the Context of drug-delivery formulation design.
The beauty of ROMP is its ability to integrate the mitochondrial targeting ligand or the fluorescent tag, or
any other desirable functional groups, orthogonally to the polymerization process. If ROMP was conducted
under living polymerization conditions, the desirable functional groups are controllably and homogenously
incorporated into polymer molecules in a bottom-up approach. Use of nanoscopic formulations with homogenous
distribution of the desired functional group(s) in biological experiments generates reproducible data, creating
more opportunity for new insights.
2.2. Challenges in Translation from Pre-clinical Evaluation to Clinical Use
After toxicity and efficacy of drug delivery formulations are assessed in animal models, human
trials are initiated, the outcome of which can be communicated to request an FDA approval for
marketing purposes. Clinical trials are broken into three main stages that build on one another: a
dosing, toxicity and excretion in healthy subjects stage (phase I); a safety and efficacy in a larger group of
patients with the target illness stage (phase II); and a multi-center, randomized and placebo-controlled
stage (phase III) [146]. We surveyed the clinical trial database available at the ClinicalTrials.gov
repository in April 2019, bearing in mind that the status of trials changes over time, using search
terms centered around the BBB. We cross-checked the outcome with recently published reviews in
the area of drug delivery formulations to assess the progress in the field of drug delivery to the
CNS [147,148]. We listed a glimpse of the survey findings, which we believe is of relevance to the
scope of this review (Table 1). A number of drug delivery formulations that were designed to deliver
therapeutics to the CNS by exploiting the innate transcytosis capacity of ECs have been granted
approval to undertake clinical trials. The transition of CNS-targeting formulations, such as ANG1005
and SGT-53, from preclinical investigations to the clinical trials pipeline is indicative of the feasibility
of transporter-mediated transcytosis approach. Nonetheless, the scarce number of successful clinical
trial transitions of transporter-mediated transcytosis formulations suggests that the extrapolation of
data generated from animal studies to humans is encountering significant challenges. Thus, what
are the key challenges in CNS-targeted drug delivery development that can delay the translation of
preclinical findings to clinical use?
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Table 1. Highlights of clinical trial survey showcasing the progress of CNS-drug delivery approaches.
Study Purpose Year a Phase Ref.
1. Evaluation of delivery of anti-Aβ with the aid of MA-FUS in patientswith AD 2017 Phase I/II [149]
2.
Evaluating the safety and preliminary efficacy of Onivyde®
(a nanoliposomal irinotecan) administered in combination with
temozolomide in the treatment of patients with
recurrent glioblastoma
2017 Phase I/II [150]
3.
Evaluating the safety and efficacy of spherical nucleic
acid-conjugated gold nanoparticles (NU-0129) at the treatment of
patients with recurrent glioblastoma multiforme or gliosarcoma
2017 Early Phase I [151]
4.
Evaluating brain uptake of temozolomide pre and post transient BBB
disruption mediated by administration of regadenoson, a vasoactive
peptide, in recurrent high-grade glioma patients
2015 Early Phase I [152]
5.
Evaluating brain uptake of chemotherapeutics upon transient BBB
disruption mediated by MRI-guided laser ablation in pediatric
patients with brain tumors
2015 Phase I [153,154]
6.
Evaluating brain uptake and efficacy of Pembrolizumab, an anticancer
MAb, upon transient BBB disruption mediated by MRI-guided laser
ablation in patients with recurrent malignant gliomas
2015 Phase I/II [155,156]
7.
Evaluating the efficacy of etirinotecan pegol at CNS disease control in
patients with refractory brain metastases and advanced lung cancer
or metastatic breast cancer
2015 Phase II [157,158]
8. Evaluating the effect of deep transcranial magnetic stimulation on thepermeability of the BBB in glioblastoma multiform patients 2014 Phase II [159,160]
9.
Evaluating brain uptake and efficacy of SGT-53, a cationic liposome
encapsulating a therapeutic genetic material and decorated with
anti-HTfR-MAb fragment, at the induction of apoptosis in patients
with recurrent glioblastoma when combined with temozolomide
2014 Phase II [161]
10.
Evaluating brain uptake and efficacy of doxorubicin upon transient
BBB disruption mediated by MRI-guided laser ablation in patients
with recurrent malignant gliomas
2013 Phase I [162]
11. Evaluating the efficacy of Safinamide in the treatment of patientswith PD 2009 Phase III [163,164]
12.
Evaluation of efficacy of rituximab, an anticancer MAb, given
together with methotrexate to treat patients with brain lymphoma
after its intraventricular administration
2007 Phase I [165,166]
13.
Evaluation of safety, tolerability, pharmacokinetic and BBB
permeability of ANG1005 in patients with recurrent or progressive
malignant glioma
2007 Phase I/II [167–171]
14.
Dose optimization of melphalan given together with carboplatin and
etoposide phosphate to treat patients with anaplastic
oligodendroglioma or oligoastrocytoma after transient BBB
disruption mediated by administration of mannitol
2005 Phase I/II [172–174]
15.
Evaluation of side effects of methotrexate, rituximab, and carboplatin,
given together to treat patients with primary CNS lymphoma after
transient BBB disruption mediated by administration of mannitol
2005 Phase I/II [175]
16.
Evaluating the effect of combination therapy of Doxil® and
temozolomide in addition to radiotherapy in patients diagnosed
with glioblastoma
2002 Phase I/II [176,177]
17.
Side effect evaluation and dose optimization of melphalan
administered to treat patients with brain malignancies after transient
BBB disruption mediated by administration of mannitol
1998 Phase I [178]
a Clinical trial starting date was chosen considering that most of the trials listed are not yet completed.
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2.2.1. Safety Liabilities due to Nonspecific Body Distribution
In freshly isolated human erythrocytic cells, glycosyl conjugates of chlorambucil 8 and 9 were
shown to inhibit the uptake of d-[14C]glucose in a concentration-dependent manner [81]. The interaction
of glycosylated chlorambucil esters 8 and 9 with the GLUTs was concluded to be in the form of a
non-transported inhibitor [81]. In an independent study, mice treated with TfR-MAb suffered from
a marked decrease in immature reticulocyte count relative to mice treated with non-immune IgG
control [179]. Reticulocytes develop into red blood cells through erythropoiesis; a process that requires
maintaining iron homeostasis [180]. The indiscriminate uptake of transporter-mediated transcytosis
formulations was reported in several pre-clinical studies to extend beyond constituents of the circulatory
system to encompass major body organs such as spleen and liver which is conceivable due to ubiquitous
expression of protein transporters in several body regions [91,118,119,181–195]. These phenomena
raise efficacy and safety concerns associated with the peripheral uptake of these formulations and
their competition with natural substrates for the binding to carrier or receptor proteins. It is clear
thus far that transporter-mediated transcytosis approach can improve brain uptake of the therapeutic
payload. However, consequent to their indiscriminate uptake profile among major body organs,
can transporter-mediated transcytosis formulations, under the currently employed experimental
conditions, allow the therapeutic payload to consistently and robustly attain a therapeutically effective
concentration in the brain? If so, would the aforementioned transient nutritional deprivation be a
tolerable compromise? Alternatively, how can the chemical structure of the transporter-mediated
formulation be tailored to find a good balance between efficacy and safety?
2.2.2. Inadequate Endothelial-Parenchymal Transport
Brain permeability under saturable uptake processes such as transporter-mediated transcytosis is
often described by Equation (2) where PS is the brain permeability surface, CPf is the concentration of
test solute in the perfusate, Vmax is the maximal rate of the saturable component of transport, Km is the
perfusate concentration at which half maximal transport occurs, and Kd is the non-saturable diffusion
uptake clearance [39]. Based on this conception, drug-conjugates had been formulated to possess high
affinity, therefore low Km values, towards the target protein transporter [91,121]. However, recent
findings emerged to contradict with this conception revealing that high affinity towards the protein
transporter, such as TfR, that is not easily reversed may obstruct the release of the drug-conjugate
from the abluminal membrane which is the final stage of the transcytosis pathway [196]. In parallel
preclinical studies employing in vitro models, strong binding to TfR was shown to trigger lysosomal
sorting which may contribute to the obstructed transcellular trafficking observed in vivo [197–199].
These findings invalidate previous communications and invite researchers in this field to; (1) Study
structure-function relationship of drug-conjugates in more detail in the context of transport across
the BBB to brain parenchyma, and (2) Critically analyze their brain uptake assessment protocols in an
attempt to account for such discrepancies.
PS =
Vmax
Km + Cp f
+ Kd (2)
2.2.3. How We Measure Drug Transport across the BBB
Brain uptake of a test substrate via a specific transport mechanism can be estimated in animal
models through behavioral assays or radiolabeling experiments. Behavioral assays are used to measure
brain permeability as a function of the potency of an intravenously or intraperitoneally injected test
substrate at reducing the severity of, delaying the onset to or reverting symptoms induced by exposure
to noxious stimuli [77–79,95,117]. Radiolabeling experiments, which is the more conventional method,
directly measure brain uptake of a radiolabeled test substrate relative to a differentially-radiolabeled
reference using a liquid scintillation counter [83,87,91,94,99,117]. The differentially-radiolabeled
reference can be BBB-impermeable, the use of which corrects for artifactual BBB permeability induced
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under experimental conditions or during brain tissue sampling and processing [94,117,196,197].
To assess the nature of the transport mechanism of the test substrate, whether it’s competitive or
non-competitive, a differentially-radiolabeled and BBB-permeable agent transported via the same
mechanism as the test substrate is used as a second reference [83,84]. Radiolabeling experiments
employ complementary techniques, such as capillary depletion, to distinguish the fraction of the
test substrate that has successfully bypassed the BBB from the fraction that has been sequestered by
ECs. The concentration of the test substrate accumulated in brain tissue, Cbr, can be calculated using
Equation (3), where Cp(T) designates blood or plasma concentration at the sampling time T, by fitting
the experimentally determined distribution volume of the test substance, VD, and reference, V0 [39].
Cbr = (VD −V0) ×Cp(T) (3)
However, data generated from radiolabeling experiments should be interpreted with caution
as multiple factors involved in the experimental design can lead to erroneous interpretation of
results [200–204]. Such factors range from poor recovery of the radioactive material from tissue
samples to errors in sample analysis due to quenching of radiolabeled substance during radioactivity
measurements [203]. The factor that remains the most detrimental is the degradation of the radiolabeled
tracer into radiolabeled metabolites that can traverse brain barriers via alternate transvascular transport
mechanisms [203]. This phenomenon leads to overestimation of brain uptake of the parent radiolabeled
substance via the scrutinized mechanism which results in discrepancies amongst preclinical findings.
Perhaps investigation may be accurately conducted if a metabolic profile of the circulating test substrate
and its metabolites is obtained by plasma sample collection at multiple time intervals [203]. Alternatively,
the use of chromatographic techniques such as capillary electrophoresis may comprehensively and
simultaneously assess brain uptake of the test substrates and its metabolites [202]. The cerebrovascular
transport of the scrutinized substrate can be studies in its intact for using in situ brain perfusion
technique (Box 2) [83,84,87,99,117].
Box 2. Approaches to Reducing Metabolic Liability of Test Substrates.
In situ brain perfusion technique was developed to minimize the mixing of the infused test substrate with
endogenous plasma, reducing its metabolic degradation [83,84,87,99,117]. In this technique, blood circulation to
the brain in a fully anesthetized animal model is taken over by an infusion of oxygenated physiological buffer.
This can be accomplished by ligation of external and internal carotid artery branches, direct catheterization of the
carotid artery, and right before starting the infusion, the heart ventricles are severed to stop endogenous blood
from mixing with the infusate. Brain is perfused for a brief period, typically 60–120 s, with the physiological
buffer containing the test and reference substrates, then washed for 30 s to remove unbound material from
brain vasculature. Animals are sacrificed, decapitated, and their brains are removed and prepared to assess
their content of radioactive substrates. Albeit suitable for studying the kinetics of the unidirectional uptake of
intact substrate, this technique does not fully describe what the injected therapeutic material undergoes in a
biological environment.
2.2.4. Species Differ in Parameters that control the BBB permeability
Studies employing quantitative-targeted absolute proteomics (QTAP) coupled with Liquid
chromatography–tandem mass spectrometry (LC–MS/MS) revealed that the expression level of
functional proteins such as eﬄux pump, SLC and receptor proteins generally varies amongst different
species such as rats, mice, monkeys and humans (Box 3) [75,76,205,206]. The differential expression of
BBB proteins is paralleled with a varied brain uptake of substrates across different species. Higher brain
distribution of radiolabeled P-gp substrates such as 11C-verapamil and 18F-altanserin was detected in
the brains of healthy humans and monkeys compared to rodents [75,207]. Not only the species must
be carefully selected before designing an experiment, but also the route of administration. The basis of
this selection must be elaborated in the study as the administration route constitutes an important
variable that may significantly influence the results (Box 4).
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2.2.5. BBB Protein Expression is Altered under Different Pathological Conditions
BBB breakdown has been identified in many patients with various neurological disorders through
functional imaging and postmortem analysis. Neuroimaging studies that employ dynamic contrast
enhanced-magnetic resonance imaging (DCE-MRI) showed an increase in brain uptake of gadolinium,
an MRI tracer, amongst individuals diagnosed with different neurological diseases which is an
indicative of capillary leakage (Box 4) [16,208–216]. Independent studies using positron emission
tomography (PET) reported the detection of a diminished glucose uptake and impaired P-gp function
in the brains of AD and PD patients [16,217–224]. Neuroimaging using arterial spin labeling- magnetic
resonance imaging (ASL-MRI) revealed that patients diagnosed with neurological diseases suffer
from abnormal brain perfusion and reduced cerebral blood flow which can further aggravate BBB
damage [225–233]. Postmortem analysis of brain samples that belonged to patients diagnosed with
different neurological diseases and showed no symptoms of mixed dementia demonstrated perivascular
deposits of blood-derived proteins deemed toxic to neuronal function [234–241]. This observation was
often accompanied with degeneration of BBB structural components such as ECs, TJs, pericytes and
basement membrane along with dissociation of astrocytic end-feet from capillaries [242–256].
Box 3. Outstanding Questions.
• How does microvessel composition of carrier proteins, receptors and acidic and neutral lipids in the brain
compare to microvessel composition in other major body organs, such as kidneys, liver, spleen and lungs,
and how does this vary among different species?
• What is the significance of pathological BBB breakdown in the context of targeted drug delivery? Can BBB
breakdown act as a gateway for therapeutic access?
• Is the downregulation of transporters activity a phenotypic hallmark of a dysfunctional BBB?
• How does the alteration of transporters’ activity progress with the aggravation of disease state and how
does it vary under different pathological conditions?
• How would advances in the knowledge surrounding pathological BBB breakdown shape the future of
research being conducted to exploit the CMT and RMT capacity of ECs in the context of drug delivery
through the BBB?
Box 4. Influence of Drug Administration Route.
There is a sequence of events that any consumed drug must follow before it elicits its therapeutic effect.
Events include administration, release from its physical form, absorption from the site of administration into
the body, and finally accumulation at the site of action [257]. The route of administration is the first point of
access and the first stage at which the drug bioavailability, a measure of systemic availability of a drug, is
dictated. The route of administration and how it contributes to the success of drug delivery to the CNS is
not within the scope of this review, crucial though it is, only because we believe that it requires a dedicated
review to grant this factor the attention it deserves. We can still emphasize the complexity of coordinating the
physicochemical properties necessary for optimal drug pharmacokinetics and pharmacodynamics, which can
be further complicated when the route of administration is factored in the drug development process. Drugs
administered orally, intravenously, subcutaneously, transdermally, intracarotidly or nasally will encounter
different en route factors that can influence their dissolution, their release from their physical form, their stability
and their absorption [257]. For instance, in oral administration, which is the most popular route of drug dosing,
factors such as digestive enzymes, gastric acid, stomach-emptying rate and intestinal motility regulate the rate of
drug absorption, metabolism and disposition via the gastrointestinal tract [257]. Consequently, the ideal analysis
of the structure-function relationship must accommodate the various administration route-associated factors,
not only the nature of the drug and the formulation design.
3. Conclusions
The blood-brain barrier, the meningeal or subarachnoid barrier and the choroid plexus barrier
work in consortium to maintain cerebral homeostasis and vital brain functions. Due to its large surface
area and its faster blood flow rate, the BBB is considered as the primary contributor to the brain’s
strict permeability. The BBB is a continuous layer of endothelial cells fused together by virtue of their
tight junction proteins. The BBB is a dynamic assembly whose integrity is modulated in response to
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neuronal needs. Due to the growing population of patients affected with neurodegenerative diseases,
an urgent need for drug delivery strategies that can bypass the BBB has emerged. The progress
achieved thus far is divided into surgical approaches that can deliver the therapeutic material beyond
the BBB using specialized catheters or implantable pumps, and pharmacological approaches that
exploit endogenous transport mechanisms to deliver the therapeutic material through the BBB
(Table 2). Surgical approaches are invasive and often fraught with technical complications accompanied
with inevitable, and sometimes permanent, damage to nearby tissues, as well as tissue infection.
Pharmacological approaches tackle drug delivery through the BBB by either altering the therapeutic
material’s physicochemical properties to facilitate its passive diffusion through the LBL, attenuating
the eﬄux power by co-administration of eﬄux-pump inhibitors, increasing BBB permeability by its
transient disruption, or the ligation of the therapeutic material to a vector whose interaction with EC
transporters can trigger a transcytosis event.
Altering the physicochemical properties of therapeutic materials is often guided by computational
methods derived from the retrospective analysis of CNS and non-CNS active drugs that are commercially
available or still undergoing clinical trials. Albeit effective, these methods are still limited by the
number of predictive descriptors (lipophilicity, H-bonding, rotatable bonds, etc.), which narrows down
the window of drug discovery to encompass a small set of molecules and preclude any serious attempts
to explore molecules beyond its limits. The long-term effect of downregulation of eﬄux-pumps
activity, especially in treatment regimens that requires constant and repeated exposure to the inhibitors,
is yet to be determined. Similarly, how the inhibition of eﬄux-pumps ubiquitously expressed in
cerebral and peripheral human tissues can alter the pharmacokinetics of the therapeutic material is
yet to be unveiled. By the same analogy, the long-term effect of transient BBB disruption, induced by
hyperosmosis or microbubble-assisted focused ultrasound, and the resilience of the BBB after repeated
and consecutive disruption events remain to be investigated.
Formulations that can elicit a transcytosis event by interacting with EC transporters are designed
to target solute carriers, receptors or negatively charged transmembrane proteins. The choice of the
target transporter depends on many variables, such as the size and the chirality of the drug-conjugate
and whether the ability to mimic the transporter’s natural substrate is essential, or not, to stimulate the
binding of the formulation to the target transporter. Sophisticated formulations developed to effectively
ferry neurotherapeutics across brain barriers have had promising preclinical success, however, they are
still struggling to push their way forth towards clinical use. This brings up an important question—what
can we do to facilitate the extrapolation of data generated from animal studies to humans to realize the
full potential of this approach?
First of all, information surrounding microvessels composition of carrier proteins, receptors
and acidic lipids in major body organs and how it varies under different pathological conditions is
sorely lacking. Additionally, preliminary proteomic analysis conducted across multiple species have
emphasized species differences in protein expression and suggest that the behavior of test substrates
in a human setting may be better predicted in apes than in rodents. The knowledge of microvessel
composition and how it varies amongst different species and under different pathological conditions
will ultimately guide the optimization of drug-formulation properties to reduce off-site distribution
and minimize safety liabilities.
Moreover, development of a range of transporter-specific radioactive tracers that are metabolically
stable during the experimental timeframe may further advance the use of neuroimaging technologies,
providing more insight into how transporters activity can be altered with age and under different
pathological conditions. The library of transporter-specific radioactive tracers needs to be expanded to
encompass substrates of various protein transporters—not only GLUTs and P-gp—that can be used to
monitor and detect changes in the activity of various transporters.
Furthermore, brain uptake quantification methods need to be thoroughly and critically assessed
prior to embarking on a preclinical in vivo experiment. The injected test substrate can undergo
numerous elimination pathways, some of which may generate several metabolites. If autoradiography
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or liquid scintillation counting or any other radio-labeling based techniques is the method of choice, then
researchers need to verify the isotopic purity of the radiolabeled tracer prior to its administration, make
sure that the radiolabeled isotope does not reside at a metabolically labile position, and scrutinize and
establish the metabolic profile of the radiolabeled tracer under the employed experimental conditions
using orthogonal techniques, perhaps chromatographic, to account for the presence of any radiolabeled
metabolites. Standardizing experimental parameters is imperative to avoid any discrepancies resulting
from overestimation of brain uptake of the radiolabeled tracer.
Transvascular transport to brain lesions across the BBB is a unique process compared to drug
transport to lesions in peripheral tissues. It requires the drug-conjugate to successfully bypass
the luminal membrane, traverse the intracellular space evading lysosomal sorting and subsequent
degradation, and finally bypass the abluminal membrane, whilst maintaining the viability of the
transporting cells. In depth analysis of the structure-function relationship in the context of transvascular
transport and what it entails of transporter protein binding and dissociation kinetics is a prerequisite for
a successful drug-conjugate design, and pre-clinical studies that investigate this relationship are scarce.
The transcytosis-mediated transport approach may be regarded by some as an unfulfilled fantasy,
yet the idea, and the attempts generously dedicated to realizing it, have advanced our knowledge
of transvascular drug delivery and drug-formulation engineering and how the structure of delivery
vectors can be tailored to evade lysosomal sorting, achieving a complete and successful transcytosis
event. Therefore, because of the success achieved thus far and the potential room for improvement in
the way we plan and execute our in vivo experiments, it is premature to deem this approach infeasible.
Table 2. Summary of CNS drug delivery techniques.
NS Drug Delivery Techniques
Drug Delivery Beyond The BBB
1. Intraparenchymal Delivery
Pros • Delivery of both small and large therapeutic molecules
Cons • Invasive
• May be associated with infection or inevitable tissue damage
• Fraught with technical complications
• Requires inpatient care and overnight hospitalization
• Not suitable for a treatment regimen that requires repeated and constant exposure to the therapeutic material
2. Intrathecal and Intraventricular Delivery
Pros • Delivery of both small and large therapeutic molecules
• May require a single operation for surgical implantation of the catheter, which reduces the risk of braintissue damage
Cons • Invasive
• May be associated with infection if the patient’s body rejects the implanted reservoir of catheter
• Cost-effective for a small population of patients
• May require inpatient care and overnight hospitalization, depending on the patient’s case
3. Intranasal Delivery
Pros • Non-invasive
• Suitable for a treatment regimen that requires repeated and constant exposure to the therapeutic material
• No precedence of tissue damage associated with the technique
• Ease of application thus greater patience comfort and compliance
• Practically an outpatient treatment protocol
• Cost effective
Cons • Limited by the small amount of drug that can diffuse through the nasal cavity and reach the transportingnerves (olfactory or trigeminal) compared to the administered amount
Drug Delivery Through the BBB
1. Modification of Physicochemical Properties
Pros • Exploits the passive diffusion through LBL of ECs, which is a non-invasive and non-saturable drugdelivery modality
Cons • Limited by physicochemical properties that can be altered
• Excludes molecules, which could be of tremendous therapeutic value, with physicochemical properties that donot agree with computationally derived models
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Table 2. Cont.
NS Drug Delivery Techniques
Drug Delivery Through the BBB
2. Inhibition of Eﬄux Protein Pumps
Pros • None-invasive
• Can be co-administered with the drug to attenuate the activity of eﬄux proteins
• Ease of administration, thus greater patience comfort and compliance
Cons • Down-regulation of eﬄux transporters’ activity may increase brain uptake of potentially toxic material
3. Transient Disruption of BBB
Pros • Reversible
• No-permanent damage reported to date
• Non-invasive (compared to direct injection methods)
Cons • The CNS remains unprotected against blood-borne toxins during the therapeutic timeframe
• May require inpatient care and overnight hospitalization depending on the patient’s case
3.1. Hyperosmotic Disruption
Pros • Cost effective
Cons • Non-specific
• Associated with transient cerebral edema
3.2. MRI-Guided MA-FUS Disruption
Pros • Less invasive
• More specific
Cons • Time consuming and expensive due to FUS beam aberration corrections, multiple MRI acquisitions andultrasound and MRI contrast agents’ injections
4. Transporter-Mediated Transcytosis
Pros • Non-invasive
Cons • A saturable process
• Nonspecific body distribution due to ubiquitous expression of transporters in several body regions
• May improve brain uptake but not to the therapeutically and clinically effective concentration of the cargo(subject to further investigation)
4.1. Solute Carrier-Mediated Transcytosis
Pros • Solute carriers’ expression levels, glucose in particular, are significant relative to receptor proteins, whichmakes them an ideal target
Cons • Sensitive to the vector’s stereochemical conformation, rigidity and ligation regiochemistry of its cargo
• Restricted by the cargo’s size which should mimic that of its natural substrates
• Vector-drug ligation may result in loss of vectors affinity towards the protein carrier
• Vector-drug conjugates may compete with natural substrates for carrier binding, which may result in seriousnutritional deprivation
4.2. Receptor-Mediated Transcytosis
Pros • Transport is not restricted by the vector’s or cargo’s stereochemical conformation or size; therefore, it is suitablefor the transport of small molecules, as well as recombinant proteins
• More diverse with respect to vectors design (e.g., a monoclonal antibody, a fragment of the antibody or apeptide derived from natural substrates)
Cons • Limited capacity due to the limited receptor expression levels compared to solute carriers
• May be accompanied with acute clinical signs due to competition with natural substrates, which questions thesafety of RMT-conjugates
• Lysosomal sorting may occur preventing exocytosis of the cargo and potentially degrading the RMT vector andthe conjugated therapeutic material
4.3. Adsorptive-Mediated Transcytosis
Pros • Transport is not restricted by the vector’s or cargo’s stereochemical conformation or size, which makes itsuitable for the transport of small molecules, as well as peptides
• Binding sites are saturated at higher concentrations in AMT than in CMT and RMT
• No precedence of interference with cell signaling pathways
Cons • CPP may bind to serum proteins which can mask their positive charge and ultimately reduce their brain uptake
Funding: This research received no external funding.
Acknowledgments: We would like to thank our funders: Alzheimer’s Scotland, Alzheimer’s Society, Rosetrees
Trust and RS MacDonald Charitable Trust.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
Int. J. Mol. Sci. 2019, 20, 3108 30 of 43
Abbreviations
ATP Adenosine Triphosphate
AMT Adsorptive-mediated Transcytosis
AD Alzheimer’s Disease
HIR-MAb Anti-human Insulin Receptor Monoclonal Antibody
TfR-MAb Anti-transferrin Receptor Monoclonal Antibody
AUC0T Area under the Plasma Drug Concentration-time Curve
ASL-MRI Arterial Spin labelling Coupled Magnetic Resonance Imaging
ABC ATP-binding Cassette Transporters
BBB Blood Brain Barrier
BCSFB Blood Cerebrospinal Fluid Barrier
Cbr Brain Concentration
BCRP Breast Cancer Resistance Protein
CMT Carrier-mediated Transcytosis
CNS Central Nervous System
CSF Cerebrospinal Fluid
Ð Dispersity Index
DCE-MRI Dynamic Contrast Enhanced Magnetic Resonance Imaging
EC Endothelial Cell
EPO Erythropoietin
GLUT Glucose Transporter
GFP Green Fluorescent Protein
IR Insulin Receptor
ISF Interstitial Fluid
l-DOPA l-3,4-dihydroxyphenylalanine
LAT Large Neutral Amino Acid Transporter
LBL Lipid Bilayer
LRP Lipoprotein Receptor-related Protein
LC-MS/MS Liquid Chromatography Coupled Mass Spectrometry
LDLR Low-density Lipoprotein Receptor
MB-FUS Microbubble-assisted Focused Ultrasound
MCT Monocarboxylate Transporter
MRP Multidrug Resistance-associated Protein
NPBA Nanoscopic Polymeric Brush Architectures
NMDA N-methyl-D-aspartate
Mn Number Average Molecular Weight
OTAP Organic-anion-transporting Polypeptide
PD Parkinson Disease
P-gp P-glycoprotein
PET Positron-emission Tomography
QTAP Quantitative-targeted Absolute Proteomics
RV Rabies Virus
RVG Rabies Virus Glycoprotein
RMT Receptor-mediated Transcytosis
ROMP Ring Opening Metathesis Polymerization
siRNA Small Interfering Ribonucleic Acid
SLC Solute Carrier Transporter Proteins
TJ Tight Junction
TfR Transferrin Receptor
FDA U S Food and Drug Administration
VFR Virulence Factor Receptor
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